Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 113Neoplasm Metastasis 5Carcinoma, Intraductal, Noninfiltrating 5Polycystic Ovary Syndrome 4Ovarian Neoplasms 4Osteoporosis 4Neoplasms 4Infertility 4Breast Neoplasms, Male 4Arthralgia 4Fallopian Tube Neoplasms 3Triple Negative Breast Neoplasms 2Pain 2Leiomyosarcoma 2Leiomyoma 2Endometrial Neoplasms 2Cystadenocarcinoma, Serous 2Breast Carcinoma In Situ 2Bone Diseases, Metabolic 2Advanced Breast Cancer 2Uterine Neoplasms 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Cysts 1Osteitis Deformans 1Obesity 1Multiple Endocrine Neoplasia Type 1 1Medullary cystic kidney disease 1 1Lymphoma, Non-Hodgkin 1

Interventions

Letrozole 1Goserelin 1Erlotinib Hydrochloride 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hormone-sensitive Metastatic Breast Cancer × Letrozole × Clear all
NCT01205685 2012-09-11

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase 2 Terminated
11 enrolled 9 charts
Breast

Hormone-sensitive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡